4D pharma plc (LON: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, has today announced that David Norwood, Duncan Peyton and Alex Stevenson have purchased ordinary shares in the Company as listed below. Following this transaction, the Directors have a resulting interest in the ordinary shares of the Company as listed below.
|Name||Shares in 4D pharma plc before purchase||% of total shares in issue||Shares in 4D pharma plc after purchase||% of total shares in issue|
|David Norwood (Chairman)||7,103,725||10.85%||7,108,725||10.85%|
|Duncan Peyton (CEO)||6,343,985||9.69%||6,445,184||9.84%|
|Alex Stevenson (CSO)||6,362,138||9.71%||6,413,136||9.79%|
Founded in February 2014, 4D is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D Pharma plc has developed a proprietary platform, MicroRx®, that rationally identifies novel bacteria based on a deep understanding of function and mechanism. 4D’s Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D has three clinical studies in progress, namely a Phase II clinical study of Blautix® in Irritable Bowel Syndrome, a Phase I/II study of MRx0518 in combination with Keytruda® in solid tumours and a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours. Other focus programmes include disease areas such as asthma and CNS disease.